Mini-review - Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation

被引:111
作者
Wolff, SN [1 ]
机构
[1] Aastrom Biosci Inc, Ann Arbor, MI 48106 USA
关键词
graft failure; graft rejection; second HSC transplant;
D O I
10.1038/sj.bmt.1703389
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Failure to engraft after hematopoietic stem cell transplantation (graft dysfunction) or to sustain engraftment (graft rejection) is a formidable complication due to many possible factors. These include inadequate stem cell numbers, infections, graft-versus-host disease and immunological mediated processes. Fortunately, this complication is uncommon and can be overcome by additional hematopoietic stem cell infusions. Multiple treatment alternatives have been explored including hematopoietic growth factors, additional infusions of stem cells alone, with augmented immunosuppression or with additional cytotoxic therapy. Various sources of the additional stem cells are feasible including the original donor, using another donor, using stem cells collected from the marrow or after cytokine mobilization from the peripheral blood. This report will overview this complication and review the various studies that have attempted to define both cause and therapy. However, a lack of well-designed prospective studies has made definitive recommendations difficult although basic principles have been established.
引用
收藏
页码:545 / 552
页数:8
相关论文
共 97 条
[51]  
Lipton JH, 1997, EUR J HAEMATOL, V58, P133
[52]   2ND BONE-MARROW TRANSPLANTATION FOR LEUKEMIC RELAPSE WITHOUT GRAFT-VS-HOST DISEASE PROPHYLAXIS [J].
MAHON, FX ;
MARIT, G ;
VIARD, F ;
BERNARD, P ;
REIFFERS, J .
AMERICAN JOURNAL OF HEMATOLOGY, 1993, 43 (04) :324-325
[53]  
MARIJT WAF, 1995, BONE MARROW TRANSPL, V16, P125
[54]   Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: A report from the European blood and marrow transplant (EBMT) severe aplastic anaemia working party [J].
Marsh, J ;
Schrezenmeier, H ;
Marin, P ;
Ilhan, O ;
Ljungman, P ;
McCann, S ;
Socie, G ;
Tichelli, A ;
Passweg, J ;
Hows, J ;
Raghavachar, A ;
Locasciulli, A ;
Bacigalupo, A .
BLOOD, 1999, 93 (07) :2191-2195
[55]   Involvement of donor T-cell cytotoxic effector mechanisms in preventing allogeneic marrow graft rejection [J].
Martin, PJ ;
Akatsuka, Y ;
Hahne, M ;
Sale, G .
BLOOD, 1998, 92 (06) :2177-2181
[56]  
MARTINO R, 1994, BONE MARROW TRANSPL, V14, P589
[57]   2ND BONE-MARROW TRANSPLANTATION IN 8 CHILDREN [J].
MATTOT, M ;
NINANE, J ;
VERMYLEN, C ;
CORNU, G .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1992, 9 (04) :353-357
[58]  
MCCANN SR, 1994, BONE MARROW TRANSPL, V13, P233
[59]  
MCGLAVE P, 1993, BLOOD, V81, P543
[60]   Outcome of acute leukemia relapsing after bone marrow transplantation: Utility of second transplants and adoptive immunotherapy [J].
Mehta, J ;
Powles, R ;
Treleaven, J ;
Horton, C ;
Meller, S ;
Pinkerton, CR ;
Singhal, S .
BONE MARROW TRANSPLANTATION, 1997, 19 (07) :709-719